TGTX logo

TGTXTG Therapeutics Inc

$40.59
$3.95
(10.78%)
Today
Updated: 02:55 PM EDT
Reported EarningsMay 6
Mkt Cap$5.61B
Vol2.31M
News
all
press releases
TGTX Stock Applies Brakes On 5-Session Losing Streak – Retail Eyes ‘Multi-Billion’ Sales As At-Home Multiple Sclerosis Treatment Gets Boost
The company announced positive Phase 1 results for a subcutaneous formulation of Briumvi, evaluating it against the currently approved IV formulation.
Stocktwits
News Placeholder
More News
News Placeholder
TGTX's Single-Dose Briumvi Hits Bioequivalence Goal in MS Study
TG Therapeutics announces that Briumvi's late-stage ENHANCE study met its goal, supporting a potential single-infusion regimen for relapsing MS patients.
Zacks
News Placeholder
TGTX Stock Rises 29% in 3 Months: Here's What You Should Know
TG Therapeutics gains on strong Briumvi sales growth, higher 2026 revenue guidance and advancing late-stage studies in RMS.
Zacks
News Placeholder
TGTX Q1 Earnings Miss, Sales Rise Y/Y, Stock Up on Raised 2026 View
TG Therapeutics misses Q1 earnings estimates, but strong Briumvi sales drive y/y revenues. Shares rise as the company raises 2026 revenue outlook.
Zacks
News Placeholder
TG Therapeutics (NASDAQ:TGTX) Reaches New 1-Year High - Time to Buy?
TG Therapeutics (NASDAQ:TGTX) Reaches New 1-Year High - Here's Why...
MarketBeat
News Placeholder
TGTX Stock Hits Fresh 52-Week High – Here’s Why Retail Is Bullish Despite Q1 Earnings Miss
The company increased its U.S. sales forecast for Briumvi to $885 - $900 million, up from the earlier $825 - $850 million range
Stocktwits
News Placeholder
TG Therapeutics (TGTX) Q1 Earnings Lag Estimates
TG Therapeutics (TGTX) delivered earnings and revenue surprises of -26.88% and +2.81%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
TG Therapeutics Inc. Q1 Profit Climbs
(RTTNews) - TG Therapeutics Inc. (TGTX.OB) released earnings for its first quarter that Increased, from last year...
Nasdaq News: Markets
News Placeholder
Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need diseases, today reported financial results for the first quarter ended March 31, 2026, and provided a...
Business Wire
News Placeholder
Pictet Asset Management Holding SA Trims Stock Position in TG Therapeutics, Inc. $TGTX
Pictet Asset Management Holding SA lowered its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 9.2% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 1,461,048 shares of the biopharmaceutical company's stock after selling 148,503 sha...
MarketBeat
<
1
2
...
>